TNFRSF10D and neoplasm: Because conventional chemotherapeutic drugs have long been known for their ability to increase or restore TRAIL sensitivity in tumor cells [16], and even to overcome resistance induced by DcR2 [86], additional clinical trials have been set up to evaluate the efficacy of dulanermin combined with chemotherapy [16].